The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
mRNA stability in mammalian cells
Abstract
This review concerns how cytoplasmic mRNA half-lives are regulated and how mRNA decay rates influence gene expression. mRNA stability influences gene expression in virtually all organisms, from bacteria to mammals, and the abundance of a particular mRNA can fluctuate manyfold following a change in the mRNA half-life, without any change in transcription. The processes that regulate mRNA half-lives can, in turn, affect how cells grow, differentiate, and respond to their environment. Three major questions are addressed. Which sequences in mRNAs determine their half-lives? Which enzymes degrade mRNAs? Which (trans-acting) factors regulate mRNA stability, and how do they function? The following specific topics are discussed: techniques for measuring eukaryotic mRNA stability and for calculating decay constants, mRNA decay pathways, mRNases, proteins that bind to sequences shared among many mRNAs [like poly(A)- and AU-rich-binding proteins] and proteins that bind to specific mRNAs (like the c-myc coding-region determinant-binding protein), how environmental factors like hormones and growth factors affect mRNA stability, and how translation and mRNA stability are linked. Some perspectives and predictions for future research directions are summarized at the end.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Microinjection of CRISPR/Cas9 RNA components into cells results in a finite duration of action owing to the natural decay of mRNA within eukaryotic cells.
“With some exceptions, microinjection of CRISPR/Cas9 RNA components into cells results in a finite duration of action of the system, owing to the natural decay of mRNA within eukaryotic cells (Ross, 1995).”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Ross, 1995
Citations
Cites
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
Gossen, M., & Bujard, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5547 · Cited by 4,943 · cited 2×
“Since tetracycline rapidly represses tetracycline-responsive promoters in tissue culture cells (128) and has no apparent toxicity in animals at the required doses (118), this technique could become the method of choice, particularly as the production of transgenic mice becomes less expensive and more widespread.”
BackgroundMethodNagy, E., & Rigby, W. F. C. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.6.2755 · Cited by 361
Wang, X., Kiledjian, M., Weiss, I. M., & Liebhaber, S. A. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.3.1769 · Cited by 192
Flagged first, then by citations
Cited by
Sorted by citations
AU-rich elements: characterization and importance in mRNA degradation
Chen, C.-Y. A., & Shyu, A.-B. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89102-1 · Cited by 1,948
Delivering CRISPR: a review of the challenges and approaches
Lino, C. A., Harper, J. C., Carney, J. P., & Timlin, J. A. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1474964 · Cited by 1,185
Brennan, C. M., & Steitz*, J. A. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000854 · Cited by 1,095
Developing mRNA-vaccine technologies
Schlake, T., Thess, A., Fotin-Mleczek, M., & Kallen, K.-J. (2012) · RNA Biology · doi:10.4161/rna.22269 · Cited by 622
mRNA vaccines manufacturing: challenges and bottlenecks
Rosa, S. S., Prazeres, D. M. F., Azevedo, A. M., & Marques, M. P. C. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.038 · Cited by 545
mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases
Maruggi, G., Zhang, C., Li, J., Ulmer, J. B., & Yu, D. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.020 · Cited by 507
Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs
Lal, A., Mazan‐Mamczarz, K., Kawai, T., Yang, X., Martindale, J. L., & Gorospe, M. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600305 · Cited by 461
Njie, E. G., Boelen, E., Stassen, F. R., Steinbusch, H. W. M., Borchelt, D. R., & Streit, W. J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.008 · Cited by 335
Predicting RNA-seq coverage from DNA sequence as a unifying model of gene regulation
Linder, J., Srivastava, D., Yuan, H., Agarwal, V., & Kelley, D. R. (2025) · Nature Genetics · doi:10.1038/s41588-024-02053-6 · Cited by 265
Chapter 17 Messenger RNA Half‐Life Measurements in Mammalian Cells
Chen, C. A., Ezzeddine, N., & Shyu, A. (2008) · Methods in Enzymology · doi:10.1016/s0076-6879(08)02617-7 · Cited by 256
Conserved principles of mammalian transcriptional regulation revealed by RNA half-life
Friedel, C. C., Dölken, L., Ruzsics, Z., Koszinowski, U. H., & Zimmer, R. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp542 · Cited by 230
mRNA as gene therapeutic: How to control protein expression
Tavernier, G., Andries, O., Demeester, J., Sanders, N. N., De Smedt, S. C., & Rejman, J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.10.020 · Cited by 232
Trabzuni, D., Ryten, M., Walker, R., Smith, C., Imran, S., Ramasamy, A., Weale, M. E., & Hardy, J. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07432.x · Cited by 229
Poly(A) Tail Shortening by a Mammalian Poly(A)-specific 3′-Exoribonuclease
Körner, C. G., & Wahle, E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.16.10448 · Cited by 230
Modulation of mRNA stability as a novel therapeutic approach
Eberhardt, W., Doller, A., Akool, E.-S., & Pfeilschifter, J. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.01.002 · Cited by 173
The genetic and biochemical determinants of mRNA degradation rates in mammals
Agarwal, V., & Kelley, D. R. (2022) · Genome Biology · doi:10.1186/s13059-022-02811-x · Cited by 155
Alonso, J., Sánchez de Miguel, L., Montón, M., Casado, S., & López-Farré, A. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.10.5719 · Cited by 146
Kiledjian, M., DeMaria, C. T., Brewer, G., & Novick, K. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.8.4870 · Cited by 145
Vaccination with Messenger RNA (mRNA)
Pascolo, S. (2008) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-72167-3_11 · Cited by 126
Wang, Z., & Kiledjian, M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.17.6334-6341.2000 · Cited by 113
Lai, P. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(03)00296-7 · Cited by 57
Brook, M. S., Wilkinson, D. J., Mitchell, W. K., Lund, J. L., Phillips, B. E., Szewczyk, N. J., Kainulainen, H., Lensu, S., Koch, L. G., Britton, S. L., et al. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00157.2017 · Cited by 34
Sánchez de Miguel, L., Alonso, J., González-Fernández, F., de la Osada, J., Montón, M., Rodríguez-Feo, J. A., Guerra, J. I., Arriero, M. M., Rico, L., Casado, S., et al. (1999) · Journal of Vascular Research · doi:10.1159/000025643 · Cited by 32
Intracellular localization and interaction of mRNA binding proteins as detected by FRET
David Gerecht, P. S., Taylor, M. A., & Port, J. D. (2010) · BMC Cell Biology · doi:10.1186/1471-2121-11-69 · Cited by 22
The low-density lipoprotein receptor: Emerging post-transcriptional regulatory mechanisms
Ndoj, K., Meurs, A., Papaioannou, D., Bjune, K., & Zelcer, N. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.119082 · Cited by 17
Metadata
- Authors
- Ross, J.
- Affiliations
- McArdle Laboratory for Cancer Research, University of Wisconsin, Madison 53706, USA.
- Venue
- Microbiological Reviews
- Publisher
- American Society for Microbiology
- Published
- 1995-09
- Volume
- 59
- Issue
- 3
- Pages
- 423-450
- ISSN
- 0146-0749
- Cited by
- 1,411
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review